U.S. markets closed
  • S&P Futures

    4,367.00
    +18.75 (+0.43%)
     
  • Dow Futures

    34,030.00
    +191.00 (+0.56%)
     
  • Nasdaq Futures

    15,062.00
    +52.50 (+0.35%)
     
  • Russell 2000 Futures

    2,189.00
    +12.20 (+0.56%)
     
  • Crude Oil

    70.98
    +0.69 (+0.98%)
     
  • Gold

    1,763.00
    -0.80 (-0.05%)
     
  • Silver

    22.25
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1736
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3670
    +0.0011 (+0.08%)
     
  • USD/JPY

    109.5970
    +0.1770 (+0.16%)
     
  • BTC-USD

    42,652.87
    -2,977.80 (-6.53%)
     
  • CMC Crypto 200

    1,066.72
    -67.66 (-5.96%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    29,892.89
    -607.16 (-1.99%)
     

Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepatitis B and AB-836 programs.

  • AB-729 demonstrated robust mean HBsAg reduction across all doses and dosing intervals with a favorable safety and tolerability profile, followed by a sustained plateau phase.

  • AB-729, dosed at 60 mg every eight weeks, achieved a mean HBsAg (surface antigen of the hepatitis B virus) decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every four weeks.

  • AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects and increased HBV-specific immune responses in 3/5 evaluable subjects.

  • AB-729 was generally safe and well-tolerated.

  • Arbutus will hold a conference call and webcast today at 8:00 AM E.T.

  • Price Action: ABUS shares are up 13.1% at $3.81 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.